Dyne Therapeutics, Inc. (DYN): Price and Financial Metrics


Dyne Therapeutics, Inc. (DYN): $6.70

0.19 (+2.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DYN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

DYN Stock Price Chart Interactive Chart >

Price chart for DYN

DYN Price/Volume Stats

Current price $6.70 52-week high $22.17
Prev. close $6.51 52-week low $4.30
Day low $6.36 Volume 66,221
Day high $6.72 Avg. volume 204,072
50-day MA $6.23 Dividend yield N/A
200-day MA $10.30 Market Cap 346.08M

Dyne Therapeutics, Inc. (DYN) Company Bio


Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United States.


DYN Latest News Stream


Event/Time News Detail
Loading, please wait...

DYN Latest Social Stream


Loading social stream, please wait...

View Full DYN Social Stream

Latest DYN News From Around the Web

Below are the latest news stories about Dyne Therapeutics Inc that investors may wish to consider to help them evaluate DYN as an investment opportunity.

HC Advisors, LLC Buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, ...

Investment company HC Advisors, LLC (Current Portfolio) buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, Amgen Inc, Dyne Therapeutics Inc, UnitedHealth Group Inc, sells Netflix Inc, Invesco S&P 500 Equal Weight ETF, PIMCO Energy & Tactical Credit Opportunities, Pinduoduo Inc, Alphabet Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HC Advisors, LLC.

Yahoo | February 2, 2022

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | January 22, 2022

Why Shares of Dyne Therapeutics Dropped 18.1% on Tuesday

A clinical hold regarding one of the company's therapies brought Dyne's shares to a 52-week low.

Yahoo | January 18, 2022

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

WALTHAM, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed on clinical hold its Investigational New Drug (IND) application to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51. Dyne rece

Yahoo | January 18, 2022

Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present during the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET. A live webcast will be available in the Investors & Media se

Yahoo | January 5, 2022

Read More 'DYN' Stories Here

DYN Price Returns

1-mo N/A
3-mo -30.50%
6-mo -43.65%
1-year -69.55%
3-year N/A
5-year N/A
YTD -43.65%
2021 -43.38%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.392 seconds.